<DOC>
	<DOCNO>NCT02012062</DOCNO>
	<brief_summary>The study evaluate whether concurrent nimotuzumab could decrease severe acute treatment-related toxicity compare concurrent chemoradiotherapy locoregionally advanced NPC . Three hundred twenty patient recruit study .</brief_summary>
	<brief_title>Phase â…¢ Study Neoadjuvant TPF Chemotherapy Followed Radiotherapy Concurrent Nimotuzumab Cisplatin Locoregionally Advanced Nasopharyngeal Carcinoma ( NPC ) .</brief_title>
	<detailed_description>Scheme : Eligible stage III IVA/B NPC patient first stratified institution , randomize 2 arm 1:1 ratio . - Arm Cisplatin : Neoadjuvant TPF chemotherapy ( docetaxel 75 mg/m2 , cisplatin 75 mg/m2 , 5-FU 2500 mg/m2 every 3 week 3 cycle ) , follow cisplatin 40 mg/m2/week concurrent IMRT - Arm nimotuzumab : Neoadjuvant TPF chemotherapy ( docetaxel 75 mg/m2 , cisplatin 75 mg/m2 , 5-FU 2500 mg/m2 every 3 week 3 cycle ) , follow weekly nimotuzumab 200mg concurrent IMRT</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically proven poorly differentiate undifferentiated carcinoma nasopharynx . Stage III IVA/B NPC patient KPS &gt; 70 Age 1870 AGC &gt; 2000 , platelets &gt; 100,000 , AST ALT &lt; 2 x upper normal , serum creatinine &lt; 1.5mg/dl , creatinine clearance &gt; 50ml/min Histology poorly differentiate undifferentiated carcinoma , include keratinize squamous cell carcinoma . Evidence metastasis ( clavicle distant ) clinical radiographic examination . Initial surgical treatment exclude diagnostic biopsy primary site neck disease . Patients simultaneous prior malignancy ( include basal cell carcinoma skin ) Prior radiation treatment head neck prior chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Nasopharyngeal carcinoma</keyword>
	<keyword>Neoadjuvant chemotherapy</keyword>
	<keyword>Concurrent chemotherapy</keyword>
	<keyword>Nimotuzumab</keyword>
</DOC>